Healthcare Professional Area
Erdotin

Erdotin

Erdotin® ▼ – the first new mucolytic licensed in the UK and Ireland for over 25 years1 which offers an innovative new treatment for the symptom of productive cough in acute exacerbations of COPD2.

When patients with COPD experience exacerbations, Erdotin’s Anti-adhesive* 2,3, Anti-oxidant† 2, 4-6 , Mucolytic2, 7-10(AAM) properties may offer:

Erdotin

Erdotin has a significant anti-oxidant action, demonstrated by both in vitro and in vivo studies2. Studies in vivo included small numbers.

 

Erdotin is a simple twice daily 300mg dose that can be used with or without antibiotics for ten days as an adjunct to standard care2.

*In vitro data
† Erdotin has a significant anti-oxidant action, demonstrated by both ‘in vitro’ and ‘in vivo’ studies2. Studies in vivo included small numbers


References

Back to Top
  1. Galen. Data on file
  2. Erdotin 300mg Capsules Summary of Product Characteristics
  3. Braga PC, Sasso MD, Sala MT. Effects of Erdosteine and its metabolites on bacterial adhesiveness. Arzneimittel Forschung Drug Research. 1999; 49(4): 344-50
  4. Mitrea M, Silvestro L, Savu S, Mancini C. Reduced (GSH) and oxidised (GSSG) levels in plasma and BAL of chronic bronchitic patients treated with erdosteine or N-acetylcisteine (NAC). Abstract presented at 6th Int Conference on Bronchoalveolar lavage; 1998 June 24-27; Corfu (Greece)
  5. Mancini C, Silvestro L, Savu S. Pilot study on erdosteine activity on reduced glutathione (GSH) plasmatic levels in correlation with levels of the mother compound and main metabolite (N-thiodiglycolylhomocysteine). Abstract presented at 4th European Congress of Pharmaceutical Sciences; 1998 Sept 11-13; Milan (Italy)
  6. Dal Negro, Visconti M, Micheletto C, Tognella S. Antioxidant effects of erdosteine in current smokers with mild COPD (Gold Class 0-2). Eur. Resp. Soc. Ann. Congress. 2006 September 2–6; Munich (Germany)
  7. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda D, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33(11): 612-618
  8. Mohanty KC, Thiappanna G, Singh V, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin. Research. 2001; 4: 35-39
  9. Bisetti A, Macini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivo di Medicina. Interna 1995; XLVII(4): 89-97
  10. Tellings JC. Erdosteine: original secretolytic drug with mucociliar activity: a controlled clinical study versus ambroxol. Medical Praxis. 1991; 12(4):183-95
  11. Busin S, Clerici R, Nitti F. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Medical Praxis. 1991; 12(4): 197-205

PMR – NOV – 2006 – 0241 | Date of preparation: 12 January 2007

* Bisetti A, Macini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivo di Medicina. Interna 1995; XLVII(4): 89-97
Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda D, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33(11): 612-618